Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Epithelial cell states distinguish between uterine cancers
Fri December 3rd - Two epithelial cell states have been identified that can help to distinguish between types of uterine cancer, British researchers announced last night. More
COVID-19 boosters increase immunity
Fri December 3rd - Six different types of COVID-19 boosters are safe and increase immunity following vaccination with either the AstraZeneca or Pfizer-BioNTech jabs, British researchers report today. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

UK switches vaccine strategy after thrombosis risks assessed

Thursday April 8th 2021

The UK is to offer under 30s alternatives to the Oxford adenoviral COVID-19 vaccine after confirming a small increased risk of serious thrombotic events, it was announced last night.

It came as regulators reported a significant increase in the number of reports of thrombotic events that have followed vaccination.

All the events were associated with low platelet counts, the Medicines and Healthcare products Regulatory Agency said.

It found 79 cases of thrombosis of low platelet counts including 19 deaths. These include 44 cases of cerebral venous sinus thrombosis and 35 cases of thrombosis in other major veins. The numbers represent four cases for every million doses.

The government advisers did not attempt to compare this risk with normal occurrence of these diseases – but stressed that vaccination continued hugely to reduce the risk of serious disease from COVID-19.

MHRA chief executive Dr June Raine said: “No effective medicine or vaccine is without risk. We continually monitor safety during widespread use of any vaccine. This is to ensure vaccines are performing as expected, to identify any new side effects that may arise, and to ensure the benefits continue to outweigh the risks.

“We thoroughly analyse each and every report as we receive it and although the number of reports of CVST and other thromboembolic events has increased over the last week, so has the overall number of vaccinations administered, therefore these blood clots remain extremely rare and unlikely to occur.

“We ask anyone who suspects they have experienced a side effect linked with their COVID-19 vaccine to report it to the Coronavirus Yellow Card website.”

A statement from the Joint Committee on Vaccination and Immunisation added: “Given the very low numbers of events reported overall, there is currently a high level of uncertainty in estimates of the incidence of this extremely rare adverse event by age group. However, the available data do suggest there may be a trend for increasing incidence of this adverse event with decreasing age, with a slightly higher incidence reported in the younger adult age groups.”

The committee said it would be issuing further advice for under 30s – but advised that they should be offered alternative vaccines.

British Medical Association chair Dr Chaand Nagpaul said: “It is absolutely right that the JCVI is being honest about the change of direction in advising those who are under 30 to be vaccinated with either the Moderna or Pfizer vaccine - we are fortunate that there are alternative vaccinations that can be offered to those under thirty.

“England’s Deputy Chief Medical Officer said that giving those under 30 – who are at less risk - an alternative vaccine may mean these patients have to travel further to be given it or wait a little longer to be vaccinated; it’s important that NHS England does everything it can to make this process as easy as possible so that patients will get their first and second doses so that the public can continue to have confidence in the programme.”

A government statement added: “Everybody who has already had a first dose of the AstraZeneca vaccine should receive a second dose of the same brand, irrespective of age, except for the very small number of people who experienced blood clots with low platelet counts from their first vaccination.

“The Government will follow today’s updated advice, which sets out that, as a precaution, it is preferable for people under the age of 30 with no underlying health conditions to be offered an alternative vaccine where possible once they are eligible.

“When people are called forward, they should get their jab. Vaccines are the best way out of this pandemic and provide strong protection against COVID-19.”

[MHRA statement]

Tags: Flu & Viruses | Heart Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)